Lucid Diagnostics Inc. Stock Price, News & Analysis

Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company, announced that CFO Dennis McGrath will present a corporate update at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on November 18, 2021, at 4:00 PM EST. Lucid focuses on gastroesophageal disease patients at risk of esophageal cancer, offering the EsoGuard Esophageal DNA Test alongside the EsoCheck device. Both are aimed at early cancer detection, with EsoGuard currently marketed as a Laboratory Developed Test in the U.S.

PAVmed Inc. and its subsidiary Lucid Diagnostics have provided a joint business update, announcing preliminary financial results for the six and nine months ended September 30, 2021. Both companies have recognized revenue for the first time, with PAVmed holding a 76% stake in Lucid post-IPO. Lucid raised $70 million through an IPO, and both companies collectively hold over $90 million in cash. Operating expenses for PAVmed were approximately $13.7 million, while Lucid reported $6.6 million in operating expenses. The report highlights expansions in workforce and infrastructure.

Lucid Diagnostics Inc. (Nasdaq: LUCD) has launched Lucid Test Centers in Denver, Salt Lake City, and Las Vegas, providing an office-based test for early detection of esophageal precancer in patients with GERD. This test uses EsoCheck for cell collection and EsoGuard for DNA analysis, aiming to prevent esophageal cancer. The new centers are a key part of Lucid's growth strategy, expanding from a pilot program in Phoenix. Each center is expected to operate with modest costs and contribute to increasing referrals from primary care physicians.

PAVmed Inc. and its subsidiary Lucid Diagnostics Inc. are hosting a joint business update conference call on November 16, 2021, at 4:30 PM EDT. CEO Lishan Aklog and CFO Dennis McGrath will discuss near-term milestones, growth strategies, and third quarter financial results. Lucid specializes in cancer prevention diagnostics and offers the EsoGuard Esophageal DNA Test and EsoCheck device for early detection of esophageal precancer and cancer. These innovations represent significant advancements in cancer screening for at-risk patients.

PAVmed Inc. (PAVM, PAVMZ) announced the appointment of Sunny Webb as Chief Technology Officer for its subsidiary Veris Health. Ms. Webb brings nearly two decades of experience in technology leadership, having worked with major companies like Apple and Facebook. She aims to enhance Veris' capabilities in creating integrated digital healthcare solutions for cancer patients. The company is targeting FDA clearance for its innovative implantable vascular access port by H2-2022, leveraging partnerships with Microsoft and Loka Inc. for advanced software development.

Lucid Diagnostics Inc. (Nasdaq: LUCD) appointed Dr. Suman M. Verma as Chief Scientific Officer, strengthening its leadership in cancer prevention diagnostics. Dr. Verma previously led the transfer of the EsoGuard^® Esophageal DNA Test to commercial settings. Her expertise in molecular diagnostics is expected to enhance the development of Lucid's tests for patients with gastroesophageal disease. The company is focused on advancing the early detection of esophageal cancer through its innovative diagnostic tools, including EsoGuard and EsoCheck.

Lucid Diagnostics Inc. has completed its initial public offering (IPO) on October 18, 2021, selling 5,000,000 shares at $14.00 each, raising $70 million in gross proceeds. The underwriters hold a 30-day option for an additional 750,000 shares. Lucid, a cancer prevention diagnostics company, focuses on gastroesophageal disease (GERD) patients at risk of esophageal cancer. Its EsoGuard® test is the first non-invasive diagnostic tool for early detection of esophageal precancer in at-risk patients. Cantor and Canaccord Genuity are joint book-running managers for the offering.

Lucid Diagnostics Inc. (Nasdaq: LUCD) has completed its initial public offering (IPO) on October 18, 2021, raising $70 million by selling 5 million shares at $14.00 each. The company has provided underwriters a 30-day option to acquire an additional 750,000 shares at the IPO price. Lucid, a subsidiary of PAVmed, specializes in cancer prevention diagnostics, targeting patients at risk of esophageal cancer.

The IPO was underwritten by Cantor and Canaccord Genuity, with the SEC declaring the registration statement effective on October 13, 2021.